BRAIN Biotech AG

XTRA:BNN Stock Report

Market Cap: €82.4m

BRAIN Biotech Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Aryan Moelker

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure4.8yrs
CEO ownershipn/a
Management average tenure3.2yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce

Nov 12
Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce

Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce

Sep 24
Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce

BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch

Aug 06
BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch

Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

Jun 29
Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate

Apr 19
BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate

BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable

Mar 28
BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable

Is BRAIN Biotech (ETR:BNN) A Risky Investment?

Feb 16
Is BRAIN Biotech (ETR:BNN) A Risky Investment?

Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt

Sep 13
Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt

Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like

Mar 21
Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like

Is B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Weighed On By Its Debt Load?

Feb 14
Is B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Weighed On By Its Debt Load?

When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven?

Jan 18
When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven?

How Much Did B.R.A.I.N. Biotechnology Research and Information Network's(ETR:BNN) Shareholders Earn From Share Price Movements Over The Last Three Years?

Dec 31
How Much Did B.R.A.I.N. Biotechnology Research and Information Network's(ETR:BNN) Shareholders Earn From Share Price Movements Over The Last Three Years?

Are Institutions Heavily Invested In B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shares?

Dec 10
Are Institutions Heavily Invested In B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shares?

Should You Investigate B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) At €7.30?

Nov 17
Should You Investigate B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) At €7.30?

CEO Compensation Analysis

How has Aryan Moelker's remuneration changed compared to BRAIN Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€9m

Mar 31 2024n/an/a

-€8m

Dec 31 2023n/an/a

-€8m

Sep 30 2023n/an/a

-€8m

Jun 30 2023n/an/a

-€7m

Mar 31 2023n/an/a

-€7m

Dec 31 2022n/an/a

-€7m

Sep 30 2022n/an/a

-€7m

Jun 30 2022n/an/a

-€8m

Mar 31 2022n/an/a

-€8m

Dec 31 2021n/an/a

-€4m

Sep 30 2021€957k€420k

-€5m

Jun 30 2021n/an/a

-€6m

Mar 31 2021n/an/a

-€6m

Dec 31 2020n/an/a

-€11m

Sep 30 2020€885k€280k

-€10m

Compensation vs Market: Insufficient data to establish whether Aryan's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Aryan's compensation has increased whilst the company is unprofitable.

CEO

Aryan Moelker

4.8yrs

Tenure

€957,000

Compensation

Mr. Adriaan Moelker, also known as Aryan, serves as Director of SolasCure Limited. He has been Chairman of the Management Board and Chief Executive Officer of BRAIN Biotech AG (formerly known as B.R.A.I.N....

Leadership Team

NamePositionTenureCompensationOwnership
Adriaan Moelker
Chairman of the Management Board & CEO4.8yrs€957.00kno data
Ulrich Putsch
Co-Founderno datano datano data
Michael Schneiders
CFO & Member of Management Board2.2yrsno datano data
Ute Dechert
Vice President of Human Resources & Processes4.2yrsno datano data
Jurgen Eck
Consultant5yrs€392.00kno data
Martin Langer
MD & Executive VPno datano datano data
Alexander Pelzer
VP and Head of Research & Development - Zwingenberg1.9yrsno datano data
Robbert Hoekstra
Head of Group Finance2.2yrsno datano data
Paul Scholz
Technical Lead of Genome Editing Developmentno datano datano data

3.2yrs

Average Tenure

56.5yo

Average Age

Experienced Management: BNN's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephen Catling
Independent Member of Supervisory Board4.2yrs€31.00kno data
Michael Majerus
Independent Chairman of the Supervisory Board5.8yrs€51.00kno data
Christine Uekert
Independent Supervisory Board Member1.8yrsno datano data
Anna Eichhorn
Vice Chairwoman of the Supervisory Board7.8yrs€53.00kno data
Florian Schnabel
Supervisory Board Member1.8yrsno datano data

4.2yrs

Average Tenure

57yo

Average Age

Experienced Board: BNN's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 19:36
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BRAIN Biotech AG is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Laura Lopez PinedaBaader Helvea Equity Research